Literature DB >> 29306542

Prospective study to determine early hypertrophy of the contra-lateral liver lobe after unilobar, Yttrium-90, selective internal radiation therapy in patients with hepatocellular carcinoma.

Jin Yao Teo1, John Carson Allen2, David Chee Eng Ng3, Julianah Bee Abdul Latiff4, Su Pin Choo5, David Wai-Meng Tai5, Albert Su Chong Low6, Foong Koon Cheah6, Jason Pik Eu Chang7, Juinn Huar Kam1, Victor T W Lee1, Alexander Yaw Fui Chung1, Chung Yip Chan1, Pierce Kah Hoe Chow1, Brian K P Goh8.   

Abstract

BACKGROUND: Liver resection is a major curative option in patients presenting with hepatocellular carcinoma. An inadequate functional liver remnant is a major limiting factor precluding liver resection. In recent years, hypertrophy of the functional liver remnant after selective internal radiation therapy hypertrophy has been observed, but the degree of hypertrophy in the early postselective internal radiation therapy period has not been well studied.
METHODS: We conducted a prospective study on patients undergoing unilobar, Yttrium-90 selective internal radiation therapy for hepatocellular carcinoma to evaluate early hypertrophy at 4-6 weeks and 8-12 weeks after selective internal radiation therapy.
RESULTS: In the study, 24 eligible patients were recruited and had serial volumetric measurements performed. The median age was 66 years (38-75 years). All patients were either Child-Pugh Class A or B, and 6/24 patients had documented, clinically relevant portal hypertension; 15 of the 24 patients were hepatitis B positive. At 4-6 weeks, modest hypertrophy was seen (median 3%; range -12 to 42%) and this increased at 8-12 weeks (median 9%; range -12 to 179%). No preprocedural factors predictive of hypertrophy were identified.
CONCLUSION: Hypertrophy of the functional liver remnant after selective internal radiation therapy with Yttrium-90 occurred in a subset of patients but was modest and unpredictable in the early stages. Selective internal radiation therapy cannot be recommended as a standard treatment modality to induce early hypertrophy for patients with hepatocellular carcinoma. (Surgery 2017;160:XXX-XXX.).
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29306542     DOI: 10.1016/j.surg.2017.10.014

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

Review 1.  Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review.

Authors:  Emrullah Birgin; Erik Rasbach; Steffen Seyfried; Nils Rathmann; Steffen J Diehl; Stefan O Schoenberg; Christoph Reissfelder; Nuh N Rahbari
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

2.  Small Nucleolar RNA Host Gene 1 (SNHG1) and Chromosome 2 Open Reading Frame 48 (C2orf48) as Potential Prognostic Signatures for Liver Cancer by Constructing Regulatory Networks.

Authors:  Hui Zhang; Changhua Zhuo; Dong Zhou; Mingji Zhang; Fan Zhang; Minyong Chen; Shaohua Xu; Zhaoshuo Chen
Journal:  Med Sci Monit       Date:  2020-02-09

3.  A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study.

Authors:  Armeen Mahvash; Steven Chartier; Mark Turco; Paula Habib; Steven Griffith; Scott Brown; S Cheenu Kappadath
Journal:  BMC Gastroenterol       Date:  2022-03-28       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.